Biogen (BIIB) PT Lowered to $259 at RBC Capital
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $209.83 --0%
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 6 | Down: 11 | New: 17
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 6 | Down: 11 | New: 17
Join SI Premium – FREE
RBC Capital analyst Brian Abrahams lowered the price target on Biogen (NASDAQ: BIIB) to $259.00 (from $263.00) while maintaining a Sector Perform rating.
You May Also Be Interested In
- Wolfe Research Upgrades Biogen (BIIB) to Outperform
- Entain PLC (ENT:LN) (GMVHF) PT Lowered to GBP9.14 at Deutsche Bank
- Praj Industries (PRJ:IN) PT Lowered to INR364 at JPMorgan
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
